These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2559738)

  • 41. Pharmacological actions of DPN 205-734, a novel cardiotonic agent.
    Salzmann R; Scholtysik G; Markstein R; Bormann G
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):451-60. PubMed ID: 2465446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enantiomers of 8-(3-tert-butylamino-2-hydroxypropoxy)-3,4-dihydro-3-oxo-2H- (1,4)benzothiazine: racemic resolution, chiral synthesis and biological activity.
    Schiaffella F; Fringuelli R; Cecchetti V; Fravolini A; Angeli P; Marucci G
    Farmaco; 1990 Dec; 45(12):1299-307. PubMed ID: 1982489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanism of action of OPC-8490 in human ventricular myocardium.
    Focaccio A; Peeters G; Movsesian M; Roden R; Eki Y; Krall J; Bristow MR
    Circulation; 1996 Feb; 93(4):817-25. PubMed ID: 8641012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.
    Ungerer M; Böhm M; Schwinger RH; Erdmann E
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Jun; 341(6):577-85. PubMed ID: 2392160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interactions of the enantiomers of 3-O-methyldobutamine with alpha- and beta-adrenoceptors in vitro.
    Ruffolo RR; Messick K; Horng JS
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):244-52. PubMed ID: 2991776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity.
    Sircar I; Weishaar RE; Kobylarz D; Moos WH; Bristol JA
    J Med Chem; 1987 Nov; 30(11):1955-62. PubMed ID: 2822926
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts.
    Bethke T; Brunkhorst D; von der Leyen H; Meyer W; Nigbur R; Scholz H
    Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):576-82. PubMed ID: 2457816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
    Kieback AG; Iven H; Stolzenburg K; Eichner E; Ruckdeschel W; Baumann G
    Int J Cardiol; 2003 Oct; 91(2-3):201-8. PubMed ID: 14559131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole.
    van Meel JC; Zimmermann R; Diederen W; Erdman E; Mrwa U
    Biochem Pharmacol; 1988 Jan; 37(2):213-20. PubMed ID: 2829914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inotropic and chronotropic effects of 4-(4'-n-butylaniline)-7,8- dimethoxy-5H-pyrimido[5,4-b]indole in guinea-pig atria.
    Castiella E; Frechilla D; Lasheras B; Cenarruzabeitia E; Martínez de Irujo JJ; Alberdi E; Santiago E; Monge A; Villanueva A; Martinez FJ
    J Pharm Pharmacol; 1995 Jul; 47(7):601-7. PubMed ID: 8568629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro and in vivo myocardial effects of a cyclic AMP phosphodiesterase inhibitor structurally related to natural cardenolides.
    Prigent AF; Nemoz G; Roche M; Pacheco H
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):131-52. PubMed ID: 230791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling and contractility.
    Jung AS; Quaile MP; Mills GD; Bednarik DP; Houser SR; Margulies KB
    J Pharmacol Exp Ther; 2005 Feb; 312(2):517-24. PubMed ID: 15550574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of MS-857, a new and potent cardiotonic agent, in isolated mammalian cardiac muscles.
    Kamiya J; Maruyama M; Kawai K; Kobari T
    J Cardiovasc Pharmacol; 1989 Nov; 14(5):790-7. PubMed ID: 2481195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chiral recognition of doxazosin enantiomers in 3 targets for therapy as well as adverse drug reactions in animal experiments.
    Zhao D; Duan LH; Wang FY; Wang M; Lu HG; Wu ZG; Wang X; Ren LM
    Can J Physiol Pharmacol; 2012 Dec; 90(12):1623-33. PubMed ID: 23210441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inotropic agents. Synthesis and structure-activity relationships of new milrinone related cAMP PDE III inhibitors.
    Fossa P; Boggia R; Lo Presti E; Mosti L; Dorigo P; Floreani M
    Farmaco; 1997; 52(8-9):523-30. PubMed ID: 9507660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronotropic and inotropic effects of milrinone and congeners: comparison with PDE III inhibition.
    Dorigo P; Floreani M; Belluco P; Gaion RM; Carpenedo F
    Acta Physiol Hung; 1990; 75 Suppl():85-6. PubMed ID: 2371910
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacological actions of SDZ 218-135, a novel positive inotropic agent.
    Zierhut W; Salzmann R; Bormann G; Rüegg UT; Hof RP
    Cardiovasc Drugs Ther; 1994 Apr; 8(2):235-44. PubMed ID: 7918136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphodiesterase inhibition and positive inotropy in failing human myocardium.
    Schmitz W; Eschenhagen T; Mende U; Müller FU; Neumann J; Scholz H
    Basic Res Cardiol; 1992; 87 Suppl 1():65-71. PubMed ID: 1323266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.
    Schneider J; Beck E; Heers C; Conrad C; de Chaffoy de Courcelles D; Wilffert B; Peters T
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Nov; 346(5):563-72. PubMed ID: 1470228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening of positive inotropic agents in isolated cardiac preparations from different sources.
    Böhm M; Diet F; Pieske B; Erdmann E
    J Pharmacol Methods; 1989 Mar; 21(1):33-44. PubMed ID: 2704246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.